Trial Profile
A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Elinzanetant (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Therapeutic Use
- Acronyms SWITCH-1
- Sponsors Bayer; KaNDy Therapeutics
- 08 Jan 2024 According to a Bayer media release, the Phase II study NIRVANA is based on improvements in sleep disturbances observed in this Phase IIb study SWITCH-1.
- 01 Mar 2023 Results published in the Menopause
- 02 Feb 2023 According to a Bayer media release, results from this study were presented at the 13th European Congress on Menopause and Andropause Virtual Meeting in September 2021.